Expedited Programs for
Serious Conditions-Drugs and Biologics
Extension without change of a currently approved collection
No
Regular
07/22/2024
Requested
Previously Approved
36 Months From Approved
07/31/2024
1,091
948
81,440
71,090
0
0
This ICR collects information from
sponsors and applicants who wish to obtain a priority review
designation or breakthrough therapy designation. Respondents to the
collection are manufacturers or sponsors of drug and/or biologic
products.
US Code:
21
USC 356 Name of Law: FFDCA; Expedited Approval of Drugs
Based on a review of the
information collection since our last request for OMB approval, we
have increased our burden estimate by 143 responses and 10,350
hours to reflect actual submissions we have received. We attribute
these changes to increased interest in the expedited programs.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.